Skip to main content

Table 1 Patient characteristics

From: A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

  Patients
n %
Age, years [median (range)] 78 (70–84)  
Sex
 Female 6 37.5
 Male 10 62.5
ECOG PS
 0 5 31.3
 1 5 31.3
 2 6 37.4
Histology
 Adenocarcinoma 11 68.8
 Squamous cell carcinoma 2 12.5
 Adenosquamous cell carcinoma 1 6.2
 NOS 2 12.5
Clinical stage (TNM ver.7)
 IIIB 4 25.0
 IV 11 68.8
 Post operative recurrence 1 6.2
No. of prior chemotherapy regimen
 1 15 93.8
 2 1 6.2
  1. ECOG PS Eastern Cooperative Oncology Group performance status, TNM tumor-node-metastasis, NOS not otherwise specified.